Clinical Trial Update: Efficacy and Safety of Aprotinin on Transfusion Requirements in Patients Undergoing Radical or Total Cystectomy [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating whether aprotinin reduces transfusion needs in patients undergoing radical or total cystectomy was terminated, with a report on its e…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer

Drugs mentioned

• Aprotinin (aprotinin)

Snippet

Sponsor: Bayer | Conditions: Blood Loss, Surgical, Postoperative Hemorrhage | Phase 3 | Status: TERMINATED